S4 Ep7: Utilizing Technology to Monitor Patient Safety and Improve Patient Experience in Clinical Trials – Part 1

The Elixir Factor

What is continuomics, and how can it help drive innovation and improve patient experience? Continuomics is the application of technologies to measure an individual’s physiological data in a continuous and unobtrusive manner, and that is exactly what Lilly is striving to do, and what the latest episode of The Elixir Factor will discuss.

Ensuring patient safety during clinical trials, alongside optimal patient experience, is imperative to the research and development of new, innovative treatments, as well as the overall patient experience during research. In this episode, we’ll discuss the pharmaceutical industry’s need to measure a very critical side effect in some clinical trials, heart rate, in a patient friendly way that allows for continuous and reliable monitoring of patient safety through clinical trials.

Today, guest host Brian Winger, Lilly’s Associate Vice President, Digital Health Research and Development is joined by Chuck Benson, Senior Medical Director, and Tony Fantana, Lead, Emerging Technology Strategy, Clinical Design, Delivery and Analytics (Sr. Director) who will explore how Lilly is utilizing ‘continuomics’ in attempt to change the pharmaceutical industry’s monitoring of patient safety throughout clinical trials and how one clinical trial led to important insights that could change the future of patient safety and the patient experience during clinical trials. Tune in to Part One of this two-part series to learn more and stay tuned for Part Two of this episode to launch on Thursday, September 29, one week from this episodes launch date.

Patient safety is measured, evaluated and followed in all clinical trials conducted at Lilly. The material presented in these podcasts represent emerging technology that Lilly believes may provide additional capabilities to monitor and evaluate safety and enable a different experience for clinical trial participants.